Please login to the form below

Not currently logged in
Email:
Password:

UK/Russian pharma firm launches

Global pharmaceutical company, Pro Bono Bio, has launched today with funding from UK-based Celtic Pharma and the state-owned Russian Corporation of Nanotechnologies (RusNano)

Global pharmaceutical company, Pro Bono Bio, has launched today with funding from UK-based Celtic Pharma and the state-owned Russian Corporation of Nanotechnologies (RusNano).

The company said it intends to support a 'unique humanitarian mission' with products to be priced in different areas based on the region's ability to pay.

Free drug donations will be available to countries in Africa based on the success of products sold Western Europe.

The launch of Pro Bono Bio comes at the same time as UK Prime Minister David Cameron's visit to Russia.

He said: "This is a great example of UK/Russia collaboration at the cutting edge of R&D. It demonstrates how British businesses can work together with their Russian counterparts to expand into new areas, creating jobs and prosperity here in the UK."

As part of the company's development, Pro Bono Bio said it intends to build a manufacturing plant in the UK. A further facility is also planned for Moscow.

The company is to launch its first product Flexiseq, a nanotechnology based treatment for osteoarthritis, in the UK today, with further plans to release drugs for skin disorders in the coming months.

Other pipeline products for the company include blood factors for the treatment of haemophilia as well as antibiotics for the treatment of infections such as Clostridium difficile, MRSA and tuberculosis.

12th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics